[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 406
Citations 0
News From the Centers for Disease Control and Prevention
August 7, 2013

CDC Recommends Oral Medication to Prevent HIV in Injecting Drug Users

JAMA. 2013;310(5):471. doi:10.1001/jama.2013.16974

Based on findings from a randomized controlled trial in Thailand, the Centers for Disease Control and Prevention (CDC) has recommended oral medication as pre-exposure prophylaxis (PrEP) to prevent HIV infection among injecting drug users.

The CDC recommends that injecting drug users take a daily fixed-dose combination of 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine, which is marketed as Truvada. The US Food and Drug Administration last year approved an indication for Truvada to prevent HIV infection among men who have sex with men and heterosexually active men and women. The drug is used with other anti-HIV medications to treat HIV infection in teens and adults.

First Page Preview View Large
First page PDF preview
First page PDF preview